Loading…
Accuracy and Feasibility of a Novel Glucose/Lactate Continuous Multi-Analyte Sensing Platform in Humans
Continuous glucose monitoring systems (CGMs) have been commercially available since 1999. However, automated insulin delivery systems may benefit from real-time inputs in addition to glucose. Continuous multi-analyte sensing platforms will meet this area of potential growth without increasing the bu...
Saved in:
Published in: | Journal of diabetes science and technology 2024-07, p.19322968241266822 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c282t-e263cb1279dcacb54397c239223071fb2a230821b31aeb53a71a61b90f59d8843 |
container_end_page | |
container_issue | |
container_start_page | 19322968241266822 |
container_title | Journal of diabetes science and technology |
container_volume | |
creator | Lu, Jean C Morrison, Dale Halim, Bella Manos, Georgina Obeyesekere, Varuni Kannard, Brian Shah, Rajiv Wolfe, Kate Morrow, Blake Pagliuso, Ben Liang, Bradley Nava, Bella Lee, Melissa H Ekinci, Elif Jenkins, Alicia J MacIsaac, Richard J O'Neal, David N |
description | Continuous glucose monitoring systems (CGMs) have been commercially available since 1999. However, automated insulin delivery systems may benefit from real-time inputs in addition to glucose. Continuous multi-analyte sensing platforms will meet this area of potential growth without increasing the burden of additional devices. We aimed to generate pilot data regarding the safety and function of a first-in-human, single-probe glucose/lactate multi-analyte continuous sensor.
The investigational glucose/lactate continuous multi-analyte sensor (PercuSense Inc, Valencia, California) was inserted to the upper arms of 16 adults with diabetes, and data were available for analysis from 11 of these participants (seven female; mean [SD] = age 43 years [16]; body mass index [BMI] = 27 kg/m
[5]). A commercially available Guardian 3 CGM (Medtronic, Northridge, California) was also inserted into the abdomen for comparison. All participants underwent a meal-test followed by an exercise challenge on day 1 and day 4 of wear. Performance was benchmarked against venous blood YSI glucose and lactate values.
The investigational glucose sensor had an overall mean absolute relative difference (MARD) of 14.5% (median = 11.2%) which improved on day 4 compared with day 1 (13.9% vs 15.2%). The Guardian 3 CGM had an overall MARD of 13.9% (median = 9.4%). The lactate sensor readings within 20/20% and 40/40% of YSI values were 59.7% and 83.1%, respectively.
Our initial data support safety and functionality of a novel glucose/lactate continuous multi-analyte sensor. Further sensor refinement will improve run-in performance and accuracy. |
doi_str_mv | 10.1177/19322968241266822 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11571936</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3086061817</sourcerecordid><originalsourceid>FETCH-LOGICAL-c282t-e263cb1279dcacb54397c239223071fb2a230821b31aeb53a71a61b90f59d8843</originalsourceid><addsrcrecordid>eNplUU1P3DAQtapWhVJ-ABfkYy8Bj53E8QmtVnxUWmillrM18TpbV44NsYO0_x6vWFBRTzOaefPezDxCToCdAUh5DkpwrtqO18DbEvgHcrirVQKY_LjPd4AD8iWlv4w1dSflZ3IgFJONqvkh2SyMmSc0W4phTa8sJtc77_KWxoEivYtP1tNrP5uY7PkKTcZs6TKG7MIc50RvZ59dtQjot6Xxy4bkwob-9JiHOI3UBXozjxjSV_JpQJ_s8T4ekfury9_Lm2r14_r7crGqDO94rixvhemBS7U2aPqmFkoaLhTngkkYeo4l6Tj0AtD2jUAJ2EKv2NCoddfV4ohcvPA-zP1o18aGPKHXD5MbcdrqiE6_7wT3R2_ikwZoZPlXWxi-7Rmm-DjblPXokrHeY7DlYl30W9ZCB7JA4QVqppjSZIc3HWB655D-z6Eyc_rvgm8Tr5aIZz2ajGY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3086061817</pqid></control><display><type>article</type><title>Accuracy and Feasibility of a Novel Glucose/Lactate Continuous Multi-Analyte Sensing Platform in Humans</title><source>Sage Journals Online</source><creator>Lu, Jean C ; Morrison, Dale ; Halim, Bella ; Manos, Georgina ; Obeyesekere, Varuni ; Kannard, Brian ; Shah, Rajiv ; Wolfe, Kate ; Morrow, Blake ; Pagliuso, Ben ; Liang, Bradley ; Nava, Bella ; Lee, Melissa H ; Ekinci, Elif ; Jenkins, Alicia J ; MacIsaac, Richard J ; O'Neal, David N</creator><creatorcontrib>Lu, Jean C ; Morrison, Dale ; Halim, Bella ; Manos, Georgina ; Obeyesekere, Varuni ; Kannard, Brian ; Shah, Rajiv ; Wolfe, Kate ; Morrow, Blake ; Pagliuso, Ben ; Liang, Bradley ; Nava, Bella ; Lee, Melissa H ; Ekinci, Elif ; Jenkins, Alicia J ; MacIsaac, Richard J ; O'Neal, David N</creatorcontrib><description>Continuous glucose monitoring systems (CGMs) have been commercially available since 1999. However, automated insulin delivery systems may benefit from real-time inputs in addition to glucose. Continuous multi-analyte sensing platforms will meet this area of potential growth without increasing the burden of additional devices. We aimed to generate pilot data regarding the safety and function of a first-in-human, single-probe glucose/lactate multi-analyte continuous sensor.
The investigational glucose/lactate continuous multi-analyte sensor (PercuSense Inc, Valencia, California) was inserted to the upper arms of 16 adults with diabetes, and data were available for analysis from 11 of these participants (seven female; mean [SD] = age 43 years [16]; body mass index [BMI] = 27 kg/m
[5]). A commercially available Guardian 3 CGM (Medtronic, Northridge, California) was also inserted into the abdomen for comparison. All participants underwent a meal-test followed by an exercise challenge on day 1 and day 4 of wear. Performance was benchmarked against venous blood YSI glucose and lactate values.
The investigational glucose sensor had an overall mean absolute relative difference (MARD) of 14.5% (median = 11.2%) which improved on day 4 compared with day 1 (13.9% vs 15.2%). The Guardian 3 CGM had an overall MARD of 13.9% (median = 9.4%). The lactate sensor readings within 20/20% and 40/40% of YSI values were 59.7% and 83.1%, respectively.
Our initial data support safety and functionality of a novel glucose/lactate continuous multi-analyte sensor. Further sensor refinement will improve run-in performance and accuracy.</description><identifier>ISSN: 1932-2968</identifier><identifier>EISSN: 1932-3107</identifier><identifier>DOI: 10.1177/19322968241266822</identifier><identifier>PMID: 39075942</identifier><language>eng</language><publisher>United States: SAGE Publications</publisher><subject>Original</subject><ispartof>Journal of diabetes science and technology, 2024-07, p.19322968241266822</ispartof><rights>2024 Diabetes Technology Society 2024 Diabetes Technology Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c282t-e263cb1279dcacb54397c239223071fb2a230821b31aeb53a71a61b90f59d8843</cites><orcidid>0000-0002-3985-2708 ; 0000-0002-3151-232X ; 0000-0002-0870-4032</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39075942$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lu, Jean C</creatorcontrib><creatorcontrib>Morrison, Dale</creatorcontrib><creatorcontrib>Halim, Bella</creatorcontrib><creatorcontrib>Manos, Georgina</creatorcontrib><creatorcontrib>Obeyesekere, Varuni</creatorcontrib><creatorcontrib>Kannard, Brian</creatorcontrib><creatorcontrib>Shah, Rajiv</creatorcontrib><creatorcontrib>Wolfe, Kate</creatorcontrib><creatorcontrib>Morrow, Blake</creatorcontrib><creatorcontrib>Pagliuso, Ben</creatorcontrib><creatorcontrib>Liang, Bradley</creatorcontrib><creatorcontrib>Nava, Bella</creatorcontrib><creatorcontrib>Lee, Melissa H</creatorcontrib><creatorcontrib>Ekinci, Elif</creatorcontrib><creatorcontrib>Jenkins, Alicia J</creatorcontrib><creatorcontrib>MacIsaac, Richard J</creatorcontrib><creatorcontrib>O'Neal, David N</creatorcontrib><title>Accuracy and Feasibility of a Novel Glucose/Lactate Continuous Multi-Analyte Sensing Platform in Humans</title><title>Journal of diabetes science and technology</title><addtitle>J Diabetes Sci Technol</addtitle><description>Continuous glucose monitoring systems (CGMs) have been commercially available since 1999. However, automated insulin delivery systems may benefit from real-time inputs in addition to glucose. Continuous multi-analyte sensing platforms will meet this area of potential growth without increasing the burden of additional devices. We aimed to generate pilot data regarding the safety and function of a first-in-human, single-probe glucose/lactate multi-analyte continuous sensor.
The investigational glucose/lactate continuous multi-analyte sensor (PercuSense Inc, Valencia, California) was inserted to the upper arms of 16 adults with diabetes, and data were available for analysis from 11 of these participants (seven female; mean [SD] = age 43 years [16]; body mass index [BMI] = 27 kg/m
[5]). A commercially available Guardian 3 CGM (Medtronic, Northridge, California) was also inserted into the abdomen for comparison. All participants underwent a meal-test followed by an exercise challenge on day 1 and day 4 of wear. Performance was benchmarked against venous blood YSI glucose and lactate values.
The investigational glucose sensor had an overall mean absolute relative difference (MARD) of 14.5% (median = 11.2%) which improved on day 4 compared with day 1 (13.9% vs 15.2%). The Guardian 3 CGM had an overall MARD of 13.9% (median = 9.4%). The lactate sensor readings within 20/20% and 40/40% of YSI values were 59.7% and 83.1%, respectively.
Our initial data support safety and functionality of a novel glucose/lactate continuous multi-analyte sensor. Further sensor refinement will improve run-in performance and accuracy.</description><subject>Original</subject><issn>1932-2968</issn><issn>1932-3107</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNplUU1P3DAQtapWhVJ-ABfkYy8Bj53E8QmtVnxUWmillrM18TpbV44NsYO0_x6vWFBRTzOaefPezDxCToCdAUh5DkpwrtqO18DbEvgHcrirVQKY_LjPd4AD8iWlv4w1dSflZ3IgFJONqvkh2SyMmSc0W4phTa8sJtc77_KWxoEivYtP1tNrP5uY7PkKTcZs6TKG7MIc50RvZ59dtQjot6Xxy4bkwob-9JiHOI3UBXozjxjSV_JpQJ_s8T4ekfury9_Lm2r14_r7crGqDO94rixvhemBS7U2aPqmFkoaLhTngkkYeo4l6Tj0AtD2jUAJ2EKv2NCoddfV4ohcvPA-zP1o18aGPKHXD5MbcdrqiE6_7wT3R2_ikwZoZPlXWxi-7Rmm-DjblPXokrHeY7DlYl30W9ZCB7JA4QVqppjSZIc3HWB655D-z6Eyc_rvgm8Tr5aIZz2ajGY</recordid><startdate>20240729</startdate><enddate>20240729</enddate><creator>Lu, Jean C</creator><creator>Morrison, Dale</creator><creator>Halim, Bella</creator><creator>Manos, Georgina</creator><creator>Obeyesekere, Varuni</creator><creator>Kannard, Brian</creator><creator>Shah, Rajiv</creator><creator>Wolfe, Kate</creator><creator>Morrow, Blake</creator><creator>Pagliuso, Ben</creator><creator>Liang, Bradley</creator><creator>Nava, Bella</creator><creator>Lee, Melissa H</creator><creator>Ekinci, Elif</creator><creator>Jenkins, Alicia J</creator><creator>MacIsaac, Richard J</creator><creator>O'Neal, David N</creator><general>SAGE Publications</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3985-2708</orcidid><orcidid>https://orcid.org/0000-0002-3151-232X</orcidid><orcidid>https://orcid.org/0000-0002-0870-4032</orcidid></search><sort><creationdate>20240729</creationdate><title>Accuracy and Feasibility of a Novel Glucose/Lactate Continuous Multi-Analyte Sensing Platform in Humans</title><author>Lu, Jean C ; Morrison, Dale ; Halim, Bella ; Manos, Georgina ; Obeyesekere, Varuni ; Kannard, Brian ; Shah, Rajiv ; Wolfe, Kate ; Morrow, Blake ; Pagliuso, Ben ; Liang, Bradley ; Nava, Bella ; Lee, Melissa H ; Ekinci, Elif ; Jenkins, Alicia J ; MacIsaac, Richard J ; O'Neal, David N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c282t-e263cb1279dcacb54397c239223071fb2a230821b31aeb53a71a61b90f59d8843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Original</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lu, Jean C</creatorcontrib><creatorcontrib>Morrison, Dale</creatorcontrib><creatorcontrib>Halim, Bella</creatorcontrib><creatorcontrib>Manos, Georgina</creatorcontrib><creatorcontrib>Obeyesekere, Varuni</creatorcontrib><creatorcontrib>Kannard, Brian</creatorcontrib><creatorcontrib>Shah, Rajiv</creatorcontrib><creatorcontrib>Wolfe, Kate</creatorcontrib><creatorcontrib>Morrow, Blake</creatorcontrib><creatorcontrib>Pagliuso, Ben</creatorcontrib><creatorcontrib>Liang, Bradley</creatorcontrib><creatorcontrib>Nava, Bella</creatorcontrib><creatorcontrib>Lee, Melissa H</creatorcontrib><creatorcontrib>Ekinci, Elif</creatorcontrib><creatorcontrib>Jenkins, Alicia J</creatorcontrib><creatorcontrib>MacIsaac, Richard J</creatorcontrib><creatorcontrib>O'Neal, David N</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of diabetes science and technology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lu, Jean C</au><au>Morrison, Dale</au><au>Halim, Bella</au><au>Manos, Georgina</au><au>Obeyesekere, Varuni</au><au>Kannard, Brian</au><au>Shah, Rajiv</au><au>Wolfe, Kate</au><au>Morrow, Blake</au><au>Pagliuso, Ben</au><au>Liang, Bradley</au><au>Nava, Bella</au><au>Lee, Melissa H</au><au>Ekinci, Elif</au><au>Jenkins, Alicia J</au><au>MacIsaac, Richard J</au><au>O'Neal, David N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Accuracy and Feasibility of a Novel Glucose/Lactate Continuous Multi-Analyte Sensing Platform in Humans</atitle><jtitle>Journal of diabetes science and technology</jtitle><addtitle>J Diabetes Sci Technol</addtitle><date>2024-07-29</date><risdate>2024</risdate><spage>19322968241266822</spage><pages>19322968241266822-</pages><issn>1932-2968</issn><eissn>1932-3107</eissn><abstract>Continuous glucose monitoring systems (CGMs) have been commercially available since 1999. However, automated insulin delivery systems may benefit from real-time inputs in addition to glucose. Continuous multi-analyte sensing platforms will meet this area of potential growth without increasing the burden of additional devices. We aimed to generate pilot data regarding the safety and function of a first-in-human, single-probe glucose/lactate multi-analyte continuous sensor.
The investigational glucose/lactate continuous multi-analyte sensor (PercuSense Inc, Valencia, California) was inserted to the upper arms of 16 adults with diabetes, and data were available for analysis from 11 of these participants (seven female; mean [SD] = age 43 years [16]; body mass index [BMI] = 27 kg/m
[5]). A commercially available Guardian 3 CGM (Medtronic, Northridge, California) was also inserted into the abdomen for comparison. All participants underwent a meal-test followed by an exercise challenge on day 1 and day 4 of wear. Performance was benchmarked against venous blood YSI glucose and lactate values.
The investigational glucose sensor had an overall mean absolute relative difference (MARD) of 14.5% (median = 11.2%) which improved on day 4 compared with day 1 (13.9% vs 15.2%). The Guardian 3 CGM had an overall MARD of 13.9% (median = 9.4%). The lactate sensor readings within 20/20% and 40/40% of YSI values were 59.7% and 83.1%, respectively.
Our initial data support safety and functionality of a novel glucose/lactate continuous multi-analyte sensor. Further sensor refinement will improve run-in performance and accuracy.</abstract><cop>United States</cop><pub>SAGE Publications</pub><pmid>39075942</pmid><doi>10.1177/19322968241266822</doi><orcidid>https://orcid.org/0000-0002-3985-2708</orcidid><orcidid>https://orcid.org/0000-0002-3151-232X</orcidid><orcidid>https://orcid.org/0000-0002-0870-4032</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1932-2968 |
ispartof | Journal of diabetes science and technology, 2024-07, p.19322968241266822 |
issn | 1932-2968 1932-3107 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11571936 |
source | Sage Journals Online |
subjects | Original |
title | Accuracy and Feasibility of a Novel Glucose/Lactate Continuous Multi-Analyte Sensing Platform in Humans |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T22%3A22%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Accuracy%20and%20Feasibility%20of%20a%20Novel%20Glucose/Lactate%20Continuous%20Multi-Analyte%20Sensing%20Platform%20in%20Humans&rft.jtitle=Journal%20of%20diabetes%20science%20and%20technology&rft.au=Lu,%20Jean%20C&rft.date=2024-07-29&rft.spage=19322968241266822&rft.pages=19322968241266822-&rft.issn=1932-2968&rft.eissn=1932-3107&rft_id=info:doi/10.1177/19322968241266822&rft_dat=%3Cproquest_pubme%3E3086061817%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c282t-e263cb1279dcacb54397c239223071fb2a230821b31aeb53a71a61b90f59d8843%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3086061817&rft_id=info:pmid/39075942&rfr_iscdi=true |